Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperfractionated vs Conventional RT with BCNU for Malignant Glioma
NCT03722355Phase 3Completed
- Sponsor
- NRG Oncology
- Start
- Nov 1990
- Primary completion
- Mar 1994
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of carmustine in glioma, glioblastoma multiforme (GBM) and astrocytoma (2 arms), sponsored by NRG Oncology. Primary endpoint: Overall Survival at 131 months. Started Nov 1990; status: completed.
02
Drugs
carmustine
03
Conditions
gliomaglioblastoma multiforme (GBM)astrocytoma
Beyond the preview
Go deeper on NCT03722355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03722355.